Zimmer Biomet Holdings (ZBH) drew fresh attention after its board approved a third-quarter 2026 cash dividend of $0.24 per share, providing investors with a specified payout timeline and record date.
The dividend decision comes as Zimmer Biomet Holdings trades at US$100.04, with a 90 day share price return of 19.45% and a 30 day share price return of 6.50%. However, the 1 year total shareholder return is down 4.72% and the 5 year total shareholder return is down 26.62%, suggesting that recent momentum has picked up after a weaker longer term journey.
Compare Zimmer Biomet Holdings with a hand picked list of solid balance sheet and fundamentals (52 results) to see how this dividend move stacks up against other financially resilient stocks.
Bulls see a recovering Zimmer Biomet Holdings with growing revenue and net income and a fresh dividend, while bears point to longer term share price declines. Which story does the current valuation support?
Most Popular Narrative: 7% Undervalued
Zimmer Biomet Holdings last closed at $100.04, while the most followed narrative sets fair value at $107.57 using an 8.2% discount rate. The gap reflects a view that the company’s earnings and cash generation path could support a higher valuation than today’s price implies.
The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.
Read the complete narrative. Read the complete narrative.
Want to see what sits behind that premium robotics and digital push? The fair value hinges on how revenue, margins, and earnings work together. Curious which assumptions matter most across growth, profitability, and valuation multiples?
Result: Fair Value of $107.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Zimmer Biomet Holdings still faces pricing pressure and reimbursement risk, as well as integration challenges from recent acquisitions that could weigh on margins and cash generation.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Next Steps
With both concerns and optimism around Zimmer Biomet Holdings in view, consider acting while the data is fresh and form your own balanced take using the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Zimmer Biomet Holdings?
If Zimmer Biomet Holdings has your attention, do not stop there. Use fresh screening ideas to pressure test your thinking and avoid missing other potential opportunities.
- Target potential mispricings by reviewing a focused 45 high quality undervalued stocks that highlights companies with strong fundamentals priced below their estimated worth.
- Strengthen your income toolkit by scanning a curated 12 dividend fortresses that concentrates on stocks offering higher yields with a focus on stability.
- Prioritise resilience by checking a 74 resilient stocks with low risk scores that surfaces companies with more robust balance sheets and lower risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com